letrozole has been researched along with everolimus in 45 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (17.78) | 29.6817 |
2010's | 25 (55.56) | 24.3611 |
2020's | 12 (26.67) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Boulay, A; Chen, S; Evans, DB; Lane, HA; O'Reilly, T; Rudloff, J; Ye, J; Zumstein-Mecker, S | 1 |
Lane, HA; Lebwohl, D | 1 |
Abrial, C; Chollet, P; Curé, H; Durando, X; Leheurteur, M; Mouret-Reynier, MA; Tacca, O | 1 |
Beeram, M; DeGraffenried, LA; Middleton, A; Russell, D; Tan, QT; Tekmal, RR | 1 |
Awada, A; Cardoso, F; De Grève, J; Dirix, L; Fontaine, C; Piccart, M; Sotiriou, C; Steinseifer, J; Tanaka, C; Tang, P; Wouters, C; Zoellner, U | 1 |
Collingridge, D | 1 |
Fricker, J | 1 |
Baselga, J; Bellet, M; Bianchi, G; Campone, M; Dixon, JM; Gardner, H; Greil, R; Jonat, W; Kubista, E; Lane, HA; Manikhas, A; Mayordomo, J; Molloy, B; Phillips, P; Rugo, HS; Semiglazov, V; Steinseifer, J; Stumm, M; Tokaji, E; van Dam, P | 1 |
de Azambuja, E; Metzger-Filho, O | 1 |
Airoud, K; Alfieri, RR; Andreis, D; Bertoni, R; Bonelli, MA; Bottini, A; Cavazzoni, A; Fumarola, C; Galetti, M; Galvani, E; Generali, D; Harris, AL; La Monica, S; Martin, LA; Petronini, PG; Tramonti, S | 1 |
Ito, Y | 1 |
A'Hern, R; Dowsett, M; Evans, DB; Farmer, I; Ghazoui, Z; Guest, S; Johnston, SR; Lane, HA; Martin, LA; Pancholi, S; Ribas, R; Thornhill, AM; Weigel, MT | 1 |
De, G; Diener, M; Namjoshi, M; Wu, EQ; Xie, J; Yang, H | 1 |
Bartlett, JM; Baselga, J; Dixon, JM; Loi, S; Michiels, S; Piccart, MJ; Sabine, VS; Sahmoud, T; Sims, AH; Singhal, SK; Sotiriou, C | 1 |
Hou, G; Liu, J; Liu, Y; Zhang, J; Zhang, S; Zhang, X | 1 |
Mehta, A; Tripathy, D | 1 |
Lu, XY; Xu, H; Yang, Y; Zeng, T; Zhang, ZZ | 1 |
Kaldygul Kabakovna, S; Kuanysh Shadybayevich, N; Lewis, L; Ramil Zufarovich, A; Suriya Ertugyrovna, Y; Taylor, M | 1 |
Brown, MP; Singhal, N; Vatandoust, S | 1 |
Coleman, RL; Gershenson, DM; Jiang, Y; Johnston, T; Levenback, C; Lu, KH; Munsell, MF; Nowakowski, M; Ring, K; Slomovitz, BM; Soliman, PT; Yates, MS; Zhang, Q | 1 |
Johnston, SR | 1 |
Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I | 1 |
Bregni, G; de Braud, F; Di Cosimo, S; Zanardi, E | 1 |
Batson, S; Jones, N; Livings, C; Telford, C | 1 |
Niraula, S; Ocana, A | 1 |
Block, MS; Colon-Otero, G; Copland, JA; Dinh, TA; Foster, NR; Haluska, P; Hou, X; Jatoi, A; Robertson, MW; Wahner-Hendrickson, AE; Weroha, SJ | 1 |
Chirila, C; Colosia, A; Iyer, S; Kaye, JA; Ling, C; Mitra, D; Odom, D | 1 |
Assi, T; El Rassy, E; Kattan, J; Kourie, HR; Moussa, T | 1 |
Cao, M; Deng, H; Liu, J; Rao, N; Wu, W; Yang, Y; You, N | 1 |
Efrat Ben-Baruch, N; Evron, E; Kadouri, L; Kaufman, B; Nisenbaum, B; Ryvo, L; Safra, T; Yerushalmi, R | 1 |
Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
Broaddus, RR; Coleman, RL; Fellman, BM; Iglesias, DA; Lu, KH; Slomovitz, BM; Soliman, PT; Westin, SN; Yates, MS; Yuan, Y; Zhang, Q | 1 |
Goodwin, PJ; Madariaga, A; Oza, AM | 1 |
Abou-Alfa, GK; Ang, C; Capanu, M; Chou, JF; El Dika, I; Gordan, JD; Kobos, R; LaQuaglia, MP; Ly, M; Mayer, RJ; O'Neill, AF; O'Reilly, EM; Venook, AP | 1 |
Chavez-MacGregor, M; Duan, Z; Giordano, SH; Sharma, M; Zhao, H | 1 |
Ahn, JH; Cheon, J; Jeong, JH; Jung, KH; Kim, GM; Kim, JE; Kim, SB; Koh, SJ; Lee, KS; Park, IH; Sim, SH; Sohn, J | 1 |
Jeon, SY; Lee, KS; Park, IH; Sim, SH; Yang, HN | 1 |
Habibi-Anbouhi, M; Mohammadi, E; Tabatabaei, M; Tafazzoli-Shadpour, M | 1 |
Chen, J; Deng, H; He, Z; Jin, L; Liu, J; Nie, Y; Rao, N; Su, F; Wu, W; Yang, Y; Yao, Y | 1 |
Coleman, RL; Copeland, LJ; Filiaci, VL; Finkelstein, KA; Fleury, AC; Holman, LL; Miller, DS; Moroney, JW; Muller, CY; Slomovitz, BM; Taub, MC; Walker, JL | 1 |
Cai, R; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
Avila, M; Grinsfelder, MO; Pham, M; Westin, SN | 1 |
Acosta, EP; Elkhanany, AM; Forero-Torres, A; Grizzle, WE; Li, Y; Ryan, KJ; Stringer-Reasor, EM; Theuer, CP; Vaklavas, C; Wei, S; Yang, ES | 1 |
11 review(s) available for letrozole and everolimus
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Forecasting; Humans; Immunosuppressive Agents; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Sirolimus; Triazoles | 2006 |
[Progress of molecularly targeted therapy for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2012 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Middle Aged; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Research Design; Signal Transduction; Triazoles | 2015 |
Better Together: Targeted Combination Therapies in Breast Cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2015 |
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Network Meta-Analysis; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles | 2016 |
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Targeting the PI3K Pathway in Gynecologic Malignancies.
Topics: Endometrial Neoplasms; Everolimus; Female; Genital Neoplasms, Female; Humans; Letrozole; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases | 2022 |
14 trial(s) available for letrozole and everolimus
Article | Year |
---|---|
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Drug Interactions; Everolimus; Feasibility Studies; Female; Humans; Immunosuppressive Agents; Letrozole; Male; Middle Aged; Nitriles; Sirolimus; Treatment Outcome; Triazoles | 2008 |
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Cyclin D1; Double-Blind Method; Europe; Everolimus; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Mutation; Neoadjuvant Therapy; Nitriles; Palpation; Phosphatidylinositol 3-Kinases; Phosphorylation; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Ribosomal Protein S6 Kinases; Sirolimus; Time Factors; Treatment Outcome; Triazoles; United States | 2009 |
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Everolimus; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Letrozole; Middle Aged; Mutation; Nitriles; Phosphatidylinositol 3-Kinases; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2013 |
Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Humans; Letrozole; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Nitriles; Organoplatinum Compounds; Sirolimus; Smoking; Triazoles | 2015 |
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bayes Theorem; beta Catenin; Biomarkers, Tumor; Cohort Studies; Disease-Free Survival; DNA Mutational Analysis; Endometrial Neoplasms; Endometriosis; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Immunosuppressive Agents; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles | 2015 |
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.
Topics: Administration, Oral; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Disease-Free Survival; Everolimus; Female; Humans; Letrozole; Mice; Mice, SCID; Middle Aged; Neoplasm Grading; Nitriles; Ovarian Neoplasms; Receptors, Estrogen; Triazoles; Xenograft Model Antitumor Assays | 2017 |
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; China; Clinical Protocols; Cyclophosphamide; Epirubicin; Everolimus; Feasibility Studies; Female; Fluorouracil; Humans; Letrozole; Lymphatic Metastasis; Neoadjuvant Therapy; Nitriles; Pilot Projects; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Research Design; Treatment Outcome; Triazoles; Tumor Burden | 2017 |
Everolimus Plus Letrozole for Treatment of Patients With HR
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Diarrhea; Everolimus; Exanthema; Fatigue; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Stomatitis | 2018 |
A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Estrogens; Everolimus; Humans; Letrozole; Leuprolide; Phosphatidylinositol 3-Kinases | 2020 |
Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Letrozole; Leuprolide; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Premenopause; Primary Ovarian Insufficiency; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Young Adult | 2021 |
Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circulating Tumor DNA; DNA Mutational Analysis; Everolimus; Female; Humans; Letrozole; Middle Aged; Mutation; Neoplasm Proteins; Piperazines; Pyridines | 2021 |
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cyclophosphamide; Epirubicin; Everolimus; Female; Fluorouracil; Humans; Letrozole; Middle Aged; Pilot Projects; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2021 |
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Endometrial Neoplasms; Estradiol; Estriol; Estrone; Everolimus; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases | 2022 |
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Everolimus; Female; Humans; Letrozole; Receptor, ErbB-2; Tissue Distribution | 2023 |
20 other study(ies) available for letrozole and everolimus
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Cell Proliferation; Cell Survival; Drug Interactions; Estrogens; Everolimus; Female; Humans; Immunosuppressive Agents; Letrozole; Nitriles; Protein Kinases; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles; Tumor Cells, Cultured | 2005 |
Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Nitriles; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles | 2006 |
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Flow Cytometry; Fulvestrant; Humans; Letrozole; Nitriles; Protein Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2007 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2008 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid | 2009 |
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Repair; Drug Discovery; Everolimus; Female; Genetic Predisposition to Disease; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Neoadjuvant Therapy; Nitriles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Trastuzumab; Triazoles | 2011 |
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
Topics: Aged; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Imidazoles; Immunosuppressive Agents; Letrozole; Neoadjuvant Therapy; Nitriles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2012 |
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Nucleolus; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Everolimus; Female; Health Care Costs; Humans; Letrozole; Middle Aged; Nitriles; Receptor, ErbB-2; Severity of Illness Index; Sirolimus; Treatment Failure; Triazoles; United States | 2013 |
Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study.
Topics: Animals; Apoptosis; Aromatase; Breast Neoplasms; Cell Proliferation; Drug Synergism; Elafin; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Mice; Nitriles; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2014 |
Synergistic in vitro anti-tumor effect of letrozole and everolimus on human endometrial carcinoma Ishikawa cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endometrial Neoplasms; Everolimus; Female; Humans; Letrozole; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoproteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2014 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Everolimus; Female; Humans; Kazakhstan; Letrozole; Nitriles; Postmenopause; Receptor, ErbB-2; Triazoles | 2015 |
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles | 2015 |
Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Granulosa Cell Tumor; Humans; Letrozole; Middle Aged; Nitriles; Ovarian Neoplasms; Triazoles | 2017 |
Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Everolimus; Female; Humans; Letrozole; Metformin; Middle Aged; Progression-Free Survival | 2020 |
Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?
Topics: Diabetes Mellitus, Type 2; Everolimus; Female; Genital Neoplasms, Female; Humans; Letrozole; Metformin | 2020 |
Real-World Patterns of Everolimus Use in Patients with Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Letrozole; Middle Aged; Sirolimus | 2020 |
Chemical inhibitor anticancer drugs regulate mechanical properties and cytoskeletal structure of non-invasive and invasive breast cancer cell lines: Study of effects of Letrozole, Exemestane, and Everolimus.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Cytoskeleton; Everolimus; Female; Humans; Letrozole; Tumor Cells, Cultured | 2021 |
Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Fulvestrant; Humans; Letrozole; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Toremifene | 2022 |